Especially, we investigated the dynamic molecular changes after trastuzumab-containing therapy in HER2-positive gastric cancer using paired pre- and post-treatment tumor specimens for evaluating the utility of our method to understand the effect of drug therapy involving a molecular targeted agent from the phosphoproteomic landscape. This evidence concerns the gene ERBB2 and gastric cancer.